NCT05170308 is a NA clinical trial of CO2 fractional laser in Lichen Planus Pigmentosus, sponsored by University of Texas Southwestern Medical Center.

Who is sponsoring NCT05170308?

NCT05170308 is sponsored by University of Texas Southwestern Medical Center.

What drugs are being tested in NCT05170308?

Interventions in NCT05170308: CO2 fractional laser.

What condition does NCT05170308 study?

NCT05170308 studies Lichen Planus Pigmentosus.

Is NCT05170308 still recruiting?

NCT05170308 is currently withdrawn. Last updated 2 August 2022.

Last reviewed 2022-08-02 · How we verify

NCT05170308

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fractional CO2 Laser for the Treatment of Lichen Planus Pigmentosus

Withdrawn NA Last updated 2 August 2022

What this trial tests

NA trial testing CO2 fractional laser in Lichen Planus Pigmentosus. Withdrawn.

Timeline

1 August 2022

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	University of Texas Southwestern Medical Center
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	single
Primary purpose	treatment
Start date	1 August 2022
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across United States

Drugs / interventions tested

CO2 fractional laser

Conditions studied

Lichen Planus Pigmentosus — all drugs for Lichen Planus Pigmentosus →

Sponsor

University of Texas Southwestern Medical Center

Who can join

18 and older, any sex, with Lichen Planus Pigmentosus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the safety and efficacy of fractional carbon dioxide (CO2) laser treatment for Lichen Planus Pigmentosus (LPP). LPP is a chronic pigmentary disorder typically involving the forehead, lateral cheeks, and occasionally other sun-exposed areas such as the forearms. Clinically, LPP appears as a reticulated brown to black macules and patches. Previously studied effective treatments of LPP include topical tacrolimus and corticosteroids. LPP is often recalcitrant to therapy, with chronic maintenance treatment needed to prevent repigmentation. There are few reports of laser modalities being used to treat LPP, with Nd:YAG being the only published laser modality to be attempted. Although topical therapies are relatively safe, there is a lack of satisfactory treatment options for this patient population. Fractional CO2 laser has been widely used for photoaging due to its effectiveness and high safety profile. Clinically evident improvement can be appreciated even after only one session of treatment. Ablative fractional laser resurfacing is both safe and effective for the treatment of the vascular, pigmentary and textural components of skin disorders. No data exist regarding the use of fractional CO2 laser for management of LPP. This study hopes to fulfill this purpose. The study subjects' body will be divided into two equal halves along sagittal midline section with one side receiving treatment with fractional CO2 laser (experimental) and the other left untreated (control)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CO2 fractional laser

Trials testing the same drug.

NCT05228483 — Carbon Dioxide（CO2）Fractional Laser Plus Photodynamic Therapy in Female Patients With Vulvar Lichen Sclerosus · NA · unknown
NCT05600673 — Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia Areata · Phase 1, PHASE2 · completed

Other recruiting trials for Lichen Planus Pigmentosus

Currently open trials in the same condition.

NCT04233749 — The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans · Phase 2 · recruiting

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05170308 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
Last refreshed: 2 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05170308.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing